A5050318249- Liver Disease Diagnosis and Treatment
- Liver Disease and Transplantation
- Hepatocellular Carcinoma Treatment and Prognosis
- Hepatitis C virus research
- Hepatitis B Virus Studies
- Organ Transplantation Techniques and Outcomes
- Radiomics and Machine Learning in Medical Imaging
- Pancreatic and Hepatic Oncology Research
- Nutrition and Health in Aging
- Clinical Nutrition and Gastroenterology
- MicroRNA in disease regulation
- Diet, Metabolism, and Disease
- Cancer Mechanisms and Therapy
- Circular RNAs in diseases
- Liver physiology and pathology
- Medical Imaging Techniques and Applications
- Extracellular vesicles in disease
- Cardiac Imaging and Diagnostics
- Metabolism and Genetic Disorders
- Body Composition Measurement Techniques
- Cancer Immunotherapy and Biomarkers
- Abdominal vascular conditions and treatments
- Pancreatitis Pathology and Treatment
- Liver Diseases and Immunity
- Cholangiocarcinoma and Gallbladder Cancer Studies
Nagasaki University
2015-2025
Nagasaki University Hospital
2022
National Kyushu Medical Center
2021
Fukuoka Tokushukai Hospital
2021
University of the Ryukyus University Hospital
2021
University of the Ryukyus
2021
Kurume University
2021
Saga University
2021
Kagoshima Medical Center
2021
Oita Medical Center
2021
The Wisteria floribunda agglutinin-positive human Mac-2-binding protein (WFA+-M2BP) was recently shown to be a liver fibrosis glycobiomarker with unique fibrosis-related glycoalteration. We evaluated the ability of WFA+-M2BP predict development hepatocellular carcinoma (HCC) in patients who were infected hepatitis C virus (HCV). A total 707 had been admitted our hospital chronic HCV infection without other potential risk factors determine HCC; included age, sex, viral load, genotypes, stage,...
Measurement of Wisteria floribunda agglutinin-positive human Mac-2 binding protein (WFA+-M2BP) in serum was recently shown to be a noninvasive method assess liver fibrosis. The aim this study evaluate the utility WFA+-M2BP values predict development hepatocellular carcinoma (HCC) patients who achieved sustained virological response (SVR) by interferon treatment. For purpose, we retrospectively analyzed 238 with SVR were treated our department. Serum measured at pre-treatment (pre-Tx),...
A comparison between atezolizumab plus bevacizumab (ATEZO/BEVA) and lenvatinib (LEN) for the treatment of hepatocellular carcinoma (HCC) remains unclear.This study aimed to compare therapeutic effects safety ATEZO/BEVA LEN as first-line therapies HCC.This was a retrospective analysis 810 patients with HCC who underwent (n = 186) or 624) systemic therapy March 2018 2022 at 14 facilities. After propensity score matching, 304 (ATEZO/BEVA group: n 152; 152) were analyzed.After although there no...
Abstract We examined the epidemiological trends, including distribution of sex, age, and disease etiology, in HCC incident cases, over 24 years. Data 20,547 patients (1996–2019) were analyzed this prospective study. divided study period into four 6-yearly quarters. etiology was categorized as hepatitis B virus (HBV) infection, HBV + C (HCV) HCV both negative (non-BC). The cases per quarter 4311 (21.0%), 5505 (26.8%), 5776 (28.1%), 4955 (24.1%), sequentially. Overall, 14,020 (68.2%) male....
Abstract Although the use of immune checkpoint inhibitors (ICIs)-targeted agents for unresectable hepatocellular carcinoma (HCC) is promising, individual response variability exists. Therefore, we developed an artificial intelligence (AI)-based model to predict treatment efficacy using pre-ICIs contrast-enhanced computed tomography (CT) imaging characteristics. We evaluated atezolizumab and bevacizumab in 43 patients at Nagasaki University Hospital from 2020 2022 modified Response Evaluation...
Background: Lenvatinib is currently available as the first-line treatment for advanced unresectable hepatocellular carcinoma. We evaluated relationship between its relative dose intensity (RDI) and response in clinical settings. Methods: From March 2018 to May 2019, 93 patients were administered lenvatinib at Nagasaki University Hospital related facilities. Among these, 81 (66 men, 15 women, median age 72.0) who received analyzed retrospectively. Results: Fourteen Child–Pugh grade B, had...
Atezolizumab plus bevacizumab therapy has high response rates in patients with unresectable hepatocellular carcinoma (HCC). The hepatobiliary phase of gadoxetic acid-enhanced magnetic resonance imaging (EOB-MRI) been reported to be useful as an biomarker for detecting β-catenin mutations. We evaluated whether the pretreatment EOB-MRI could predict therapeutic effect lenvatinib and atezolizumab bevacizumab.This study included 68 (lenvatinib group (n = 33) 35)). visual assessment relative...
Serum hepatitis B surface antigen (HBsAg) seroclearance is one of the ultimate goals management chronic B. We investigated kinetics serum HBsAg before in patients with B.We retrospectively analyzed 392 Japanese who had been followed for 5 years or more between 1980 and 2000. levels were measured annually using chemiluminescent enzyme immunoassay.During a median follow up 14 years, 50 demonstrated (annual incidence rate, 0.91%). Multivariate analysis baseline characteristics revealed that...
Echocardiography is necessary for portopulmonary hypertension diagnosis, and identifying patients with cirrhosis who require it challenging. In this study, we aimed to investigate the utility of total bile acid (TBA) levels as a screening tool decompensated should undergo echocardiography diagnosis.
Immune checkpoint inhibitors (ICIs) have proven to be effective treatments for various cancers, but can also elicit immune-related adverse events (irAEs). Given that severe irAEs life-threatening, biomarkers predict the occurrence of are paramount importance. ICIs affect dynamics lymphocytes, and alterations in these may play a role development severity irAEs. The aim this study was investigate correlation between changes lymphocyte counts.Information on collected from 226 ICI cases 2014...
Posttransplant liver steatosis occurs frequently and can affect patient outcome. Our aim was to clarify the risk factors for or steatohepatitis after living donor transplantation (LT) through a retrospective examination of recent 100 LT recipients their donors.Liver biopsy performed at 1 year each year, thereafter, as needed due abnormal enzyme levels, with median follow-up 4 years (2-10 years).Liver (≥5%) identified in 33 cases, 9 patients steatosis. Recipients were younger than those...
The efficacy of molecular-targeted agents (MTAs) has been demonstrated in recent years. However, the results multidisciplinary treatment including hepatic resection are still unclear. present study evaluated outcomes MTA for advanced, unresectable hepatocellular carcinoma (HCC), with goal achieving liver resection, our department.Nine patients whom Lenvatinib had administered to achieve conversion surgery HCC were included this study. patient characteristics as following: median tumor size...
Since the discovery of senescence-associated secretory phenotype, role senescent hepatic stellate cells (HSCs) in hepatocellular carcinoma (HCC) development has gained increasing attention. Similar to cytokines, extracellular vesicles (EVs) are essential for intercellular communication. However, function EVs derived from HSCs HCC progression not been extensively studied. The aims present study were characterize and determine their tumor microenvironment. Cellular senescence was induced human...
Abstract Background and Aims Mortality after sustained virological response (SVR) with interferon‐free direct‐acting antiviral (IFN‐free DAA) therapy is crucial for optimizing post‐SVR patient care, but it remains unclear, especially regarding non‐liver‐related mortality. Methods Consecutive patients from 14 institutions were stratified into three cohorts: A (without advanced fibrosis without prior HCC), B (with C (curative HCC treatment). We assessed mortality (per 1000 person‐years...
Background/Objectives: Covert hepatic encephalopathy (CHE) is associated with decreased quality of life. Detection Child–Pugh class A necessary for its early diagnosis. This study aimed to establish a simple diagnostic method CHE in patients A. Methods: One hundred liver cirrhosis without overt and sixty-eight who visited our institution were enrolled. was diagnosed using number connection test B the neuropsychiatric (NPT). Clinical data compared. Results: The volume/body surface area ratio...
Objective Sodium glucose co-transporter 2 inhibitor (SGLT-2i), recommended for patients with type diabetes, has been reported to improve the liver function test results in non-alcoholic fatty disease (NAFLD). However, long-term effects of SGLT-2i on and body weight NAFLD have not fully elucidated. In this study, we investigated patients.
Geranylgeranylacetone (GGA), an anti-ulcer drug widely used in Japan, has attracted interest because of its various therapeutic effects. Therefore, we investigated the effects GGA on human hepatic stellate cells (HSCs) vitro and a mouse model liver fibrosis.LX2, immortalized HSC line, was cultured treated with at concentrations up to 0.5 mM. After treatment, changes cellular morphology, apoptosis, fibrosis-related gene expression were assessed. Male C57BL/6 J carbon tetrachloride...
Abstract Background The level and profiles of blood free carnitine acylcarnitines, obtained by acylcarnitine analysis using tandem mass spectrometry, reflect various metabolic conditions. We aimed to examine the acylcarnitines in liver cirrhosis patients determine clinical subjective factors associated with fraction levels cirrhosis. Methods compared fractions 54 cirrhotic other laboratory test results questionnaire answers. Results In almost all patients, (C0) acetylcarnitine (C2) were...